AU Patent

AU2012203474B2 — Anti-Viral Compounds

Assigned to AbbVie Ireland ULC · Expires 2014-09-18 · 12y expired

What this patent protects

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

USPTO Abstract

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: AU2012203474B2
Jurisdiction: AU
Classification: —
Expires: 2014-09-18
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Ireland ULC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.